Clinical Trials Directory

Trials / Completed

CompletedNCT02558166

Renal Resistive Index in Patients With Shock

Relation Between the Renal Resistive Index and Markers of the Systemic Circulation, the Microcirculation, Fluid Status and of Renal Function.

Status
Completed
Phase
Study type
Observational
Enrollment
92 (actual)
Sponsor
Amsterdam UMC, location VUmc · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

This study consists of two substudies. The first substudy: 'Renal resistive index in critically ill patients with cardiogenic and septic shock' Design: cross-sectional observational Aim of this project is: 1. to determine whether critically ill patients with cardiogenic and septic shock have an elevated Renal Resistive Index and 2. to determine whether Renal Resistive Index differs between cardiogenic/hypovolemic shock and shock due to sepsis/systemic inflammation (SIRS) 3. to determine the relation between the (change in) renal vascular resistance and * Markers of the systemic - and the microcirculation * Fluid status as quantified by bioimpedance analysis * Concomitant renal function The second substudy: 'Predictive value of the Renal Resistive Index on ICU admission and its course for the development of acute kidney injury in critically ill patients with cardiogenic and septic shock' Design: longitudinal observational The aim of this project is: 1. to determine whether the renal resistance index on admission to the intensive care unit can predict the development of acute kidney injury (AKI) in critically ill patients with shock 2. to investigate if the renal resistance index on admission to the intensive care unit is an independent predictor of the development of AKI or depends on the severity and duration of shock and other known risk factors of AKI such as comorbidity and use of nephrotoxic drugs Aim of the large research project is to determine whether the Renal Resistive Index could become a monitoring tool for intervention studies aiming to prevent acute kidney injury or protect the kidney.

Detailed description

Acute Kidney Injury (AKI) is a severe complication developing in intensive care patients as a result of hypovolemic, cardiogenic or septic shock. It is defined by an abrupt decrease in kidney function. It encompasses both direct injury to the kidney as well as acute impairment of function, including decreased glomerular filtration rate (GFR). Its prevention is crucial because AKI increases morbidity and mortality (1). Mechanisms comprise ischemia/reperfusion, oxidative stress, inflammation and toxicity (2).The common pathophysiological pathway includes endothelial damage to microvessels leading to impaired macro- and microvascular flow and this will aggravate ischemia (3). Up to now, much controversy exists about * the changes in renal blood flow during different kinds of shock * the relation between renal blood flow, glomerular filtration rate and the development of AKI * the relation between renal blood flow and markers of the systemic and microcirculation In this prospective observational study, three study measurement will be performed in two groups of critically ill patients (shock and no shock). 1. The Renal Resistive Index (RRI) will be determined using Renal Doppler Ultrasound . The renal resistive index (RRI) is a sonographic index assessing resistance of the intrarenal arcuate or interlobar arteries and is used to assess renal arterial disease. It is measured as RRI = (peak systolic velocity - end diastolic velocity)/peak systolic velocity. The normal value is ≈ 0,60, with 0,70 being around the upper limits of normal. 2. The sublingual microcirculation will be quantified using side stream dark field imaging (SDF) 3. Fluid status will be determined by Bioelectrical impedance analysis (BIA) using the Akern device. In addition, routinely measured markers of circulation, renal function and fluid balance will be collected for analysis.

Conditions

Timeline

Start date
2015-08-01
Primary completion
2016-01-01
Completion
2016-02-01
First posted
2015-09-23
Last updated
2016-05-10

Locations

1 site across 1 country: Netherlands

Source: ClinicalTrials.gov record NCT02558166. Inclusion in this directory is not an endorsement.